Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment Chambers D; Paulden M; Paton F; Heirs M; Duffy S; Hunter JM; Sculpher M; Woolacott NBr J Anaesth 2010[Nov]; 105 (5): 568-75Sugammadex 16 mg kg(-)(1) can be used for the immediate reversal of neuromuscular block 3 min after administration of rocuronium and could be used in place of succinylcholine for emergency intubation. We have systematically reviewed the efficacy and cost-effectiveness and made an economic assessment of sugammadex for immediate reversal. The economic assessment investigated whether sugammadex appears cost-effective under various assumptions about the value of any reduction in recovery time with sugammadex, the likelihood of a 'can't intubate, can't ventilate' (CICV) event, the age of the patient, and the length of the procedure. Three trials were included in the efficacy review. Sugammadex administered 3 or 5 min after rocuronium produced markedly faster recovery than placebo or spontaneous recovery from succinylcholine-induced block. No published economic evaluations were found. Our economic analyses showed that sugammadex appears more cost-effective, where the value of any reduction in recovery time is greater, where the reduction in mortality compared with succinylcholine is greater, and where the patient is younger, for lower probabilities of a CICV event and for long procedures which do not require profound block throughout. Because of the lack of evidence, the value of some parameters remains unknown, which makes it difficult to provide a definitive assessment of the cost-effectiveness of sugammadex in practice. The use of sugammadex in combination with high-dose rocuronium is efficacious. Further research is needed to clarify key parameters in the analysis and to allow a fuller economic assessment.|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Androstanols/antagonists & inhibitors[MESH]|Anesthesia Recovery Period[MESH]|Child[MESH]|Child, Preschool[MESH]|Cholinesterase Inhibitors/economics/*pharmacology[MESH]|Cost-Benefit Analysis[MESH]|Drug Costs/statistics & numerical data[MESH]|Humans[MESH]|Infant[MESH]|Infant, Newborn[MESH]|Intubation, Intratracheal/*economics/methods[MESH]|Middle Aged[MESH]|Neuromuscular Blockade/*economics[MESH]|Neuromuscular Junction/*drug effects[MESH]|Neuromuscular Nondepolarizing Agents/*antagonists & inhibitors[MESH]|Randomized Controlled Trials as Topic[MESH]|Rocuronium[MESH]|Sugammadex[MESH]|Young Adult[MESH]|gamma-Cyclodextrins/economics/*pharmacology[MESH] |
